Everything about Tyrosinase-IN-12
MI-CP151 was a period 1b randomised, double-blind, placebo managed, dose-escalation, multicentre study To guage numerous intravenous doses of sifalimumab, in adult clients with dermatomyositis or polymyositis (NCT00533091). Main demo aims had been To guage the security and tolerability of sifalimumab in dermatomyositis or polymyositis patients, eve